Dr. Bertrand Tombal delivered a practical presentation titled “What Do You Need for Decision Making in mHSPC in 2026?”, focusing on how contemporary therapeutic choices in metastatic hormone-sensitive ...

Historically, treatment for metastatic prostate cancer relied heavily on androgen deprivation therapy (ADT) alone. Over time, research has demonstrated that combining ADT with additional agents ...

Researchers have found in a new study that among men with prostate cancer undergoing androgen deprivation therapy, use of oxybutynin 5 mg twice daily significantly reduced the frequency ...

Eating too many pumpkin seeds can cause stomach upset and bloating. Pumpkin seeds are high in calories, which can lead to weight gain. Allergic reactions to pumpkin seeds may cause symptoms like ...

Bayer AG (BAYRY) announced an update on their ongoing clinical study. The CHINANEO trial is a Phase 2 Bayer study in China testing how well a combo of darolutamide and hormone therapy works before ...

SBRT administered to oligometastases was associated with survival benefits in phase 2 trial participants with CRPC receiving abiraterone and ADT. For patients with oligometastatic castrate-resistant ...

A partitioned-survival lifetime model (2025 USD) compared ADT alone with seven intensification strategies across PFS, post-progression, and death, using published survival curves and literature-based ...

Multi-omics profiling of residual cancer burden after neoadjuvant hormonal therapy guides subtype-directed treatment in high-risk and locally advanced prostate cancer. Predictive associations between ...

This is an ASCO Meeting Abstract from the 2026 ASCO Genitourinary Cancers Symposium. This abstract does not include a full text component.

Short-course enzalutamide in recurrent prostate cancer slashes PSA, but PSMA-PET tumor volume misleads, raising overtreatment concerns. This interview with Ravi Madan, MD, acting deputy chief of the ...

A multi-institutional study led by Mayo Clinic and published in Cell Reports Medicine reports that pairing a next-generation immunotherapy with standard hormone therapy before surgery may help ...